苏州招聘

Responsibility:

    

1. Be responsible for the management of the company's early infrastructure suppliers, negotiate with suppliers, and establish supplier information;

2. Be responsible for demand analysis, analyze the requirements proposed by the demand department, and form inquiry documents with the demand department together;    

3. Be responsible for business negotiation, price negotiation, contract negotiation, price evaluation and quotation preparation and review according to the company's process;    

4. Be responsible for tracking the project, tracking the delivery, accelerating the procurement process, and cooperating with all departments to complete the procurement plan on time;  

5. Be responsible for completing the bidding work according to the company's process and signing the contract to ensure the supplier's cooperation with the project construction;   

6. Complete other tasks assigned by the superior.    

Qualification:

    

1. Bachelor degree or above, more than 3 years working experience, working experience in infrastructure procurement, experience in large factory room infrastructure is preferred;  

2. Familiar with procurement process, ISO9001 and other relevant systems;    

3. Have the basic knowledge of Finance and logistics, and be able to analyze the quotation of indirect materials;    

4. Proficient in purchasing work and familiar with purchasing management process;    

5. Have good communication and coordination ability, and understand the main business content and workflow of each department;   

6. Familiar with office software, ERP system is preferred.

和黄中国医药科技有限公司（简称“ 和黄医药 ”或“ Chi-Med ”）（纳斯达克 / 伦交所：HCM）是一家创新型生物医药公司，在过去20年间致力于发现和全球开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。目前，和黄医药共有8个抗癌类候选药物正在全球开发中，并在中国本土市场拥有广泛的商业网络。

和黄医药成立于2002年，为在纽约和伦敦两地上市的和黄中国医药科技有限公司（纳斯达克/伦交所： HCM）旗下专注于新药研发业务的子公司, 研发中心坐落在上海浦东张江高科技园区，海外临床开发及注册中心位于美国新泽西，具有完备的研发平台和GMP生产基地。管理团队成员均有在知名跨国医药和生物医药企业工作的经历，参与了多个全球新药研发；公司目前有500余位来自海内外，拥有丰富新药研发经验的科研人员，8大临床在研药物、 30多项临床试验在全球开展。

和黄医药是一家致力于创新药物研发的生物医药公司，专注于发现和开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。 自主研发的抗肿瘤新药呋喹替尼已于2018年9月获国家药品监督管理局批准上市，并于2019年11月获纳入国家医保药品目录。公司的其他候选药物，如索凡替尼、沃利替尼等，也已进入后期开发，有望在2020及2021年上市。